How do we treat migraine? New SIGN Guidelines

Similar documents
COMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS

Treatments for migraine

SIGN on the pharmacological management of migraine

Migraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

Management of headache

Vestibular Migraine. Information for patients and carers. Department of Neurology and Otolaryngology Aberdeen Royal Infirmary

Dubai Standards of Care (Migraine)

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.

Management options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM

Update on Diagnosis and Management of Migraines

ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา

ADVANCES IN MIGRAINE MANAGEMENT

MIGRAINE A MYSTERY HEADACHE

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary

Migrainous headache, the menstrual cycle and pregnancy. Dr Manuela Fontebasso Headache Specialist, Author and Headache Education Facilitator

Case Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches

Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital

SIGN 155 Pharmacological management of migraine. A national clinical guideline February Evidence

Faculty Disclosures. Learning Objectives. Acute Treatment Strategies

Disclosures. Triptans for Kids 5/16/13

Maternity. Migraine in pregnancy Information for women

Strategies in Migraine Care

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN

Index. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.

HEADACHE. Dr Nick Pendleton. September Headache

Migraine. A booklet for people with migraine and their carers. Consultation. Consultation. draft. draft. Scottish guidelines

Clinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.

10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY

25/09/2018 HEADACHE. Dr Nick Pendleton

Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert

Migraine Management. Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE

Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches

What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary

A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN

What You Should Know About Your HEADACHE. Learn more about headache types, triggers, and treatments, when to get help, and how to help yourself

MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache

Migraine. What are the symptoms of a migraine attack?

Ana Podgorac Belgrade, May 2012

ONZETRA XSAIL (sumatriptan) nasal powder

Reflections on NICE Headache Guideline. Dr Kay Kennis GPwSI in Headache, Bradford

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Adult with headache. Problem-specific video guides to diagnosing patients and helping them with management and prevention

Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders

SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES

Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor

HEADACHE: Benign or Severe Dr Gobinda Chandra Roy

Headache Questionnaire

Migraine much more than just a headache

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67%

How could I be having migraine when I don't have a headache?

Headache Assessment In Primary Eye Care

Triptans Quantity Limit Program Summary

Migraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification

Short Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment

Recognition and treatment of medication overuse headache

Prednisone vs. placebo in withdrawal therapy following medication overuse headache

MIGRAINE ASSOCIATION OF IRELAND HELPLINE

Understanding Migraines and Treatment Options. Simplified Diagnosis of Migraine. Migraine Prevalence American Migraine Study II

Emerging Challenges in Primary Care: Brainstorm: A Symposium on Migraine Treatment and Management

Regulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1).

Chronic Daily Headaches

Managing Headache in Acute Medicine. Ben Lovell Consultant Physician in Acute Medicine University College London Hospital

1. On how many days in the last 3 months did you miss work or school because of your headaches?

Headache is the most common symptom in patients with Idiopathic Intracranial Hypertension (IIH). Not everybody with IIH gets headache.

Headaches in Children and Adolescents. Paul Shillito

Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine

BOTULINUM TOXIN POLICY TO INCLUDE:

Migranal Nasal Spray. Migranal Nasal Spray (dihydroergotamine) Description

Treatment of Primary Headache Syndromes

Manging Migraine in Children & Adults

HEADACHE. Summary of British Association on the Study of Headaches {click to visit}

Headache. Section 1. Migraine headache. Clinical presentation

Understanding. Migraine. Amy, diagnosed in 1989, with her family.

Preventive treatment of migraine. Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA

The 45-year-old woman with monthly headaches. Anne MacGregor Barts and the London School of Medicine and Dentistry

Headaches in the Pediatric Emergency Dept

Maxalt. Maxalt / Maxalt-MLT (rizatriptan) Description. Section: Prescription Drugs Effective Date: April 1, 2016

MIGRAINE ASSOCIATION OF IRELAND. Migraine & Women. Her life can be hers AGAIN

Primary Care Adult Headache Management Pathway (formerly North West Headache Management Guideline for Adults) Version 1.0

The best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017

What is the Effectiveness of OnabotulinumtoxinA (Botox ) in Reducing the Number of Chronic Migraines (CM) in Patients Years Old?

Headache A Practical Approach

Headache. Luke Bennetto Consultant Neurologist Engineers House 13 th September 2016

TABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours

Neuralgias tend to be sudden, brief, intermittent severe, stabbing or lightning pains or electric shock sensations.

Daniel Kassicieh, DO, FAAN

National Hospital for Neurology and Neurosurgery. Migraine Associated Dizziness. Department of Neuro-otology

PAEDIATRIC ACUTE CARE GUIDELINE. Headache. This document should be read in conjunction with this DISCLAIMER

Migraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology

Transcription:

How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155

Premonitory Mood changes Fatigue Cognitive changes Muscle pain Food craving Aura Early Headache Fully reversible Dull headache Neurological changes: Nasal congestion Visual somatosensory Muscle pain Advanced Headache Postdrome Unilateral Throbbing Nausea Photophobia Phonophobia Osmophobia Fatigue Cognitive changes Muscle pain Preheadache Mild Moderate Severe Post headache Time Headache

Episodic Migraine Definitions Low frequency: 1-9 migraines per month High frequency: 10-14 migraines per month Chronic Headache (Tension type or Migraine) 15 or more days per month, for more than 3 months. Medication Overuse Headache Headache 15 or more days per month that has evolved along with the frequent use of acute medication, for more than 3 months. Usually chronic migraine pattern Not all patients fitting this criteria have MOH, ie some have frequent headache and current treatment is ineffective

Migraine Management Consider: Modifiable lifestyle triggers Acute treatment Preventative treatment

(1) Modifiable Lifestyle Triggers The case for the sensitive migraine brain Sleep disturbance Dehydration Diet Normal life events trigger or are associated with attacks in those predisposed Hunger Stress Environmental stimuli Changes in oestrogen level in women

Aura Fully reversible Neurological changes: Visual somatosensory Early Headache Dull headache Nasal congestion Muscle pain Advanced Headache Unilateral Throbbing Nausea Photophobia Phonophobia Osmophobia Preheadache Mild Moderate Severe Post headache Time Headache Treatment taken when the headache is mild is more likely to be effective

Aura Fully reversible Neurological changes: Visual somatosensory Early Headache Dull headache Nasal congestion Muscle pain Advanced Headache Unilateral Throbbing Nausea Photophobia Phonophobia Osmophobia Preheadache Mild Moderate Headache Severe Post headache Limit acute treatment to 10 days per month or 2 days per week to prevent medication overuse headache Avoid opiods and combination analgesics Time

Acute Treatment (SIGN) High dose Aspirin (900mg): NNT 8.1 Non-steroidal anti-inflammatory drugs Ibuprofen 400mg: NNT 7.2 Increase to 600mg if not effective Paracetamol 1g: NNT 12 Antiemetics Effective for headache as well as nausea Metroclopramide 10mg or Prochlorperazine 10mg Triptans First choice Sumatriptan 50mg (NNT 6.1) or 100mg (NNT 4.7) Others should be offered if not effective Should consider nasal or injectable if severe headache or early vomiting

Triptans Serotonin 5-HT 1B and 5-HT 1D receptors agonists Rapid onset short duration triptans Almotriptan 12.5mg Eletriptan 40mg or 80mg Rizatriptan 10mg Sumatriptan 50mg or 100mg (nasal / injectable) Zolmatriptan 5mg (oral / nasal) Slow onset long duration triptans Frovatriptan 2.5mg Naratriptan 2.5mg Frovatriptan half life 26 hours Naratiptan half life 6 hours Response to triptans is ideosyncratic i.e. If one does not work try another and another and...

Triptan side effects Most patients have few problems Not strong medications Common side effects Sensations of tingling, heat, heaviness, pressure, tightness of throat or chest Flushing Dizziness Feeling of weakness, fatigue Nausea and vomiting

Which triptan? Trying for the first time... Inadequate response... Sumatriptan 50-100mg Add anti emetic Side effects... Almotriptan (least side effects) Frovatriptan (slow onset) Naratriptan (slow onset) Early vomiting... Nasal Injectible Add Non-steroidal (Naproxen 500mg) Add Paracetamol Severe headaches... Rizatriptan Eletriptan Nasal / Injectable Combine with NSAID / Paracetamol Recurrence. Eletriptan (fastest acting / most potent) Combine with long acting NSAID Frovatriptan (long acting) Naratriptan (long acting)

Stepped vs Stratified High dose Aspirin / NSAID During attack Across attacks Mild Moderate Vary treatment depending on severity of the attack Triptan Severe

Rescue treatment If partly effective can repeat after 2 hours If ineffective for that attack don t use same treatment Consider... Triptan if 1 st line treatment is high dose NSAID Rectal Diclofenac Injectable May have to ride the headache out... Status Migrainosis = Migraine > 3 days Injectable Sumatriptan / Injectable anti-emetic / iv Aspirin Steroid taper (anecdotal evidence only) Regular use of analgesics can result in medication overuse headache

Medication Overuse Headache Medication overuse headache results from a desire to treat pain and carry on with work and home life! 2 common patterns: Transformed migraine Gradual increase in frequency of headache with increasing medication use, perhaps with anticipation that the next headache is starting Daily persistent headache Persistent headache in a person with known migraine with ongoing frequent medication use After a particularly bad headache After a headache that has responded poorly to treatment After treatment of non-headache pain eg shoulder injury

MOH (SIGN) Mediation overuse headache needs managed Not all people overusing acute medication have medication overuse headache Not clear what the best strategy is Evidence to support Abrupt withdrawal of overused medication and then need for preventative treatment assessed after a delay Abrupt withdrawal and start a preventative at the same time Start a preventative without withdrawal Strategy should be tailored to each individual person

(3) Preventative treatment Aim is to adjust threshold for developing headache Patient 4 Patient 1 Preventer Patient 3 Patient 2 Trigger Patient 1

Preventative Treatment Reserve for frequent disabling headaches e.g. 3-4 migraines per month Start low, go slow, aim high Minimum effective, maximum tolerated dose Use adequate dose for at least 2-3 months Combinations can be effective Not a cure! Good response is 50% reduction in headache frequency or severity

Do prophylactic medications work in MOH? No Based on observational studies Previously ineffective treatments become effective if tried again after medication withdrawal Yes Topiramate and Botox randomised controlled trials No difference between those who overused abortive medication and those who did not In practice... For the majority frequent analgesic / triptan use increases headache frequency and reduces the effectiveness of preventative treatment

Prophylaxis: 1 st line (SIGN) Propranolol Often require 80mg twice daily Main side effects : lethargy, reduced exercise tolerance Don t use in asthma Other beta blockers can also be effective Tricyclic anti-depressants Amitriptyline / Nortriptyline (aim for 1mg / kg) Main side effects: dry mouth and day time sedation Amitriptyline is useful if sleep is an issue Nortriptyline is much less likely to cause day time sedation Topiramate (should have used at least 1 previous preventative medication) Aim for 50mg twice daily, but higher doses can be helpful Can be very effective, but problems with tolerability Small number develop significant cognitive / depressive side effects

Other Prophylaxis (SIGN) Candesartan Angiotensin receptor blocker Generally very well tolerated Sodium Valproate crono Main issue is weight gain Should not use in women of child bearing age Flunarizine Unlicenced in UK Botox Not recommended for episodic migraine Recommended for the prophylactic treatment of chronic migraine where medication overuse has been addressed and patients have been appropriately treated with 3 or more oral migraine prophylactic treatments

Valproate and women (SIGN) Sodium valproate is associated with an increased risk of foetal malformations and poorer cognitive outcomes in children exposed to valproate in utero. For women who may become pregnant sodium valproate should only be considered as a prophylactic treatment when: other treatment options have been exhausted patients are using adequate contraception. Before commencing treatment women should be informed of: the risks associated with taking valproate during pregnancy the risk that potentially harmful exposure to valproate may occur before a women is aware she is pregnant the need to use effective contraception the need to seek further advice on migraine prophylaxis if pregnant or planning a pregnancy.

Calcium channel antagonist Flunarizine Widely used in Europe, Canada and South America and in Headache centres in the UK Issues Not licensed in UK Usually centrally dispensed from hospital pharmacy Effective As effective as the 1 st line agents Most effective treatment in Hemiplegic migraine / basilar and vertiginous migraine Long half life - clinical effect and side effects accumulate gradually Easy to use - start 5mg daily for 1 month increasing to 10mg daily if required Discontinuing - because of the long half life it can just be stopped and the clinical effect and any side effects gradually subside

A total of 31 injections across seven specific head and neck muscles, with a minimum dose of 155 U of BOTOX injected per patient

Double-blind phase: BOTOX vs. placebo Open-label phase: All patients on BOTOX Study week Mean change in frequency of headache days from baseline (days/28-day period) 0 0-2 -4-6 -8-10 -12-14 4 p<0.001 8 12 16 BOTOX (n=688) Placebo (n=696) p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 20 24 28 32 36 40 44 48 52 56 p<0.001 p=0.008 p=0.01 p=0.047 p=0.007 p=0.011 p=0.019 p=0.019 Mean ± standard error. The double-blind phase included 688 subjects in the BOTOX group and 696 in the placebo group. Headache days at baseline: 19.9 BOTOX group vs 19.8 placebo group, p=0.498.

Botox Effective and well tolerated Approved by NICE (National Institute for Clinical Excellence) 2012 for limited use in chronic migraine Must have tried 3 preventatives Must had addressed medication overuse 2 treatments 3 months apart >30% response continue treatment Revert to episodic migraine stop Approved by SMC (Scottish Medicines Consortium) February 2017

Other Prophylaxis (SIGN) Evidence insufficient to make a recommendation Pregabalin and SNRI Anti-depressants (Venlafaxine / Duloxetine) Pizotifen Only evidence is from old poor quality studies Widely used in primary care Evidence of no benefit Gabapentin Pooled evidence from 6 trials showed no consistent benefit over placebo

Greater occipital nerve block Combination of steroid and local anaesthetic 80mg Methylprednisolone and 20mg Lidocaine Useful as a bridging treatment or to give a period of respite Effect is temporary, but out lives the duration of the block Benefit in 60% (usually for 4-6 weeks) No effect in 40% Small number transiently worse (<5%) If effective ~80% of subsequent blocks effective In those without benefit multiple block procedure is worth considering

Preventative Medication: Summary First line Propranolol Topiramate Amitriptyline/ Nortriptyline Pizotifen (low quality evidence, but commonly used in primary care) Cupboard 2 Candesartan Flunarizine Sodium Valproate (should not be used in women who may become pregnant) Botox (Chronic Migraine only) Cupboard 3 Pregabalin Duloxetine Venlafaxine (no or inadequate evidence) Greater occipital nerve blocks (low quality evidence)

Menstrual Migraine Pure Menstrual Migraine (PMM) Migraine without aura On day 1±2 of menstruation (days -2 to +3)* At least 2/3 menstrual cycles No migraine at other times of the cycle Menstrually-related Migraine (MRM) As PMM but additional attacks with or without aura at other times of the cycle *day 1 = first day of bleeding; there is no day 0 MacGregor EA. Menstrual migraine: towards a definition. Cephalalgia 1996;16:11-21

Peri-menstrual Prophylaxis (SIGN) Triptan NNT Number of patients Frovatriptan 2.5mg daily 7.22 633 Frovatriptan 2.5mg twice daily 3.90 584 Naratriptan 1mg twice daily (1mg not available in UK use 2.5mg) 7.99 392 Zolmatriptan 2.5mg twice daily 4.98 80 Zolmatriptan 2.5mg 3 times daily 2.52 83 Inadequate evidence for mefenamic acid, naproxen or hormonal treatment (oestrogen gels and oral contraceptives)